-DOCSTART- -X- O
Background. -X- _ O
Vitamin -X- _ O
D -X- _ O
may -X- _ O
be -X- _ O
important -X- _ O
for -X- _ O
immune -X- _ O
function. -X- _ O
Studies -X- _ O
to -X- _ O
date -X- _ O
have -X- _ O
shown -X- _ O
an -X- _ O
inconsistent -X- _ O
association -X- _ O
between -X- _ O
vitamin -X- _ O
D -X- _ O
and -X- _ O
infection -X- _ O
with -X- _ O
respiratory -X- _ O
viruses. -X- _ O
The -X- _ O
purpose -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
determine -X- _ O
if -X- _ O
serum -X- _ B-Intervention
25-hydroxyvitamin -X- _ I-Intervention
D -X- _ I-Intervention
( -X- _ I-Intervention
25 -X- _ I-Intervention
( -X- _ I-Intervention
OH -X- _ I-Intervention
) -X- _ I-Intervention
D -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ O
associated -X- _ B-Outcome
with -X- _ I-Outcome
laboratory-confirmed -X- _ I-Outcome
viral -X- _ I-Outcome
respiratory -X- _ I-Outcome
tract -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
RTIs -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ O
children. -X- _ B-Patient
Methods. -X- _ O
Serum -X- _ B-Intervention
25 -X- _ I-Intervention
( -X- _ I-Intervention
OH -X- _ I-Intervention
) -X- _ I-Intervention
D -X- _ I-Intervention
levels -X- _ I-Intervention
were -X- _ O
measured -X- _ O
at -X- _ O
baseline -X- _ O
and -X- _ O
children -X- _ O
from -X- _ O
Canadian -X- _ O
Hutterite -X- _ O
communities -X- _ O
were -X- _ O
followed -X- _ O
prospectively -X- _ O
during -X- _ O
the -X- _ O
respiratory -X- _ O
virus -X- _ O
season. -X- _ O
Nasopharyngeal -X- _ O
specimens -X- _ O
were -X- _ O
obtained -X- _ O
if -X- _ O
symptoms -X- _ O
developed -X- _ O
and -X- _ O
infections -X- _ O
were -X- _ O
confirmed -X- _ O
using -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction. -X- _ O
The -X- _ O
association -X- _ O
between -X- _ O
serum -X- _ B-Intervention
25 -X- _ I-Intervention
( -X- _ I-Intervention
OH -X- _ I-Intervention
) -X- _ I-Intervention
D -X- _ I-Intervention
and -X- _ O
time -X- _ O
to -X- _ O
laboratory-confirmed -X- _ O
viral -X- _ O
RTI -X- _ O
was -X- _ O
evaluated -X- _ O
using -X- _ O
a -X- _ O
Cox -X- _ O
proportional -X- _ O
hazards -X- _ O
model. -X- _ O
Results. -X- _ O
Seven -X- _ B-Patient
hundred -X- _ I-Patient
forty-three -X- _ I-Patient
children -X- _ O
aged -X- _ O
3–15 -X- _ O
years -X- _ O
were -X- _ O
followed -X- _ O
between -X- _ O
22 -X- _ O
December -X- _ O
2008 -X- _ O
and -X- _ O
23 -X- _ O
June -X- _ O
2009. -X- _ O
The -X- _ B-Outcome
median -X- _ I-Outcome
serum -X- _ I-Outcome
25 -X- _ I-Outcome
( -X- _ I-Outcome
OH -X- _ I-Outcome
) -X- _ I-Outcome
D -X- _ I-Outcome
level -X- _ I-Outcome
was -X- _ I-Outcome
62.0 -X- _ I-Outcome
nmol -X- _ I-Outcome
/ -X- _ I-Outcome
L -X- _ I-Outcome
( -X- _ I-Outcome
interquartile -X- _ I-Outcome
range -X- _ I-Outcome
, -X- _ I-Outcome
51.0–74.0 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
A -X- _ I-Outcome
total -X- _ I-Outcome
of -X- _ I-Outcome
229 -X- _ I-Outcome
participants -X- _ I-Outcome
( -X- _ I-Outcome
31 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
developed -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
1 -X- _ I-Outcome
laboratory-confirmed -X- _ I-Outcome
viral -X- _ I-Outcome
RTI. -X- _ I-Outcome
Younger -X- _ I-Outcome
age -X- _ I-Outcome
and -X- _ I-Outcome
lower -X- _ I-Outcome
serum -X- _ I-Outcome
25 -X- _ I-Outcome
( -X- _ I-Outcome
OH -X- _ I-Outcome
) -X- _ I-Outcome
D -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
RTI. -X- _ I-Outcome
Serum -X- _ I-Outcome
25 -X- _ I-Outcome
( -X- _ I-Outcome
OH -X- _ I-Outcome
) -X- _ I-Outcome
D -X- _ I-Outcome
levels -X- _ I-Outcome
< -X- _ I-Outcome
75 -X- _ I-Outcome
nmol -X- _ I-Outcome
/ -X- _ I-Outcome
L -X- _ I-Outcome
increased -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
RTI -X- _ I-Outcome
by -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
[ -X- _ I-Outcome
HR -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
1.51 -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
[ -X- _ I-Outcome
CI -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
1.10– -X- _ I-Outcome
2.07 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.011 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
levels -X- _ I-Outcome
< -X- _ I-Outcome
50 -X- _ I-Outcome
nmol -X- _ I-Outcome
/ -X- _ I-Outcome
L -X- _ I-Outcome
increased -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
by -X- _ I-Outcome
70 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
HR -X- _ I-Outcome
, -X- _ I-Outcome
1.67 -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
, -X- _ I-Outcome
1.16–2.40 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.006 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Conclusions. -X- _ O
Lower -X- _ B-Outcome
serum -X- _ I-Outcome
25 -X- _ I-Outcome
( -X- _ I-Outcome
OH -X- _ I-Outcome
) -X- _ I-Outcome
D -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
laboratory-confirmed -X- _ I-Outcome
viral -X- _ I-Outcome
RTI -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
from -X- _ O
Canadian -X- _ O
Hutterite -X- _ O
communities. -X- _ O
Interventional -X- _ O
studies -X- _ O
evaluating -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
vitamin -X- _ O
D -X- _ O
supplementation -X- _ O
to -X- _ O
reduce -X- _ O
the -X- _ O
burden -X- _ O
of -X- _ O
viral -X- _ O
RTIs -X- _ O
are -X- _ O
warranted -X- _ O
. -X- _ O

